- Home
- BOOT vs ALKS Comparison
BOOT vs ALKS Comparison
Compare BOOT & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOOT
- ALKS
- Stock Information
- Founded
- BOOT 1978
- ALKS 1987
- Country
- BOOT United States
- ALKS Ireland
- Employees
- BOOT N/A
- ALKS N/A
- Industry
- BOOT Clothing/Shoe/Accessory Stores
- ALKS Biotechnology: Pharmaceutical Preparations
- Sector
- BOOT Consumer Discretionary
- ALKS Health Care
- Exchange
- BOOT Nasdaq
- ALKS Nasdaq
- Market Cap
- BOOT 3.3B
- ALKS 5.6B
- IPO Year
- BOOT 2014
- ALKS 1991
- Fundamental
- Price
- BOOT $100.99
- ALKS $33.62
- Analyst Decision
- BOOT Strong Buy
- ALKS Buy
- Analyst Count
- BOOT 12
- ALKS 13
- Target Price
- BOOT $180.42
- ALKS $38.50
- AVG Volume (30 Days)
- BOOT 924.2K
- ALKS 1.8M
- Earning Date
- BOOT 01-30-2025
- ALKS 04-30-2025
- Dividend Yield
- BOOT N/A
- ALKS N/A
- EPS Growth
- BOOT 4.37
- ALKS 3.47
- EPS
- BOOT 5.60
- ALKS 2.17
- Revenue
- BOOT $1,845,814,000.00
- ALKS $1,557,632,000.00
- Revenue This Year
- BOOT $17.28
- ALKS N/A
- Revenue Next Year
- BOOT $14.83
- ALKS $4.37
- P/E Ratio
- BOOT $17.77
- ALKS $15.53
- Revenue Growth
- BOOT 8.31
- ALKS N/A
- 52 Week Low
- BOOT $82.67
- ALKS $22.90
- 52 Week High
- BOOT $176.64
- ALKS $36.45
- Technical
- Relative Strength Index (RSI)
- BOOT 24.47
- ALKS 48.59
- Support Level
- BOOT $99.64
- ALKS $33.95
- Resistance Level
- BOOT $106.15
- ALKS $35.58
- Average True Range (ATR)
- BOOT 6.14
- ALKS 1.07
- MACD
- BOOT -1.34
- ALKS -0.32
- Stochastic Oscillator
- BOOT 5.56
- ALKS 22.76
About BOOT Boot Barn Holdings Inc.
Boot Barn Holdings Inc operates specialty retail stores. The company sells western and work-related footwear, apparel, and accessories in the United States. It is a single operating segment, which includes net sales generated from its retail stores and e-commerce websites.
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.